規制動向
FDA、EMA、TGA および世界の規制動向
規制動向
2026年9月18日•1分で読めます
FDA Approves ANDA211272 for Mycophenolate Mofetil Oral Suspension
Teva Pharm USA's ANDA211272 for Mycophenolate Mofetil oral suspension (200 mg/mL) received FDA approval, with several REMS and labeling supplements also approved.
規制動向
2026年9月18日•1分で読めます
FDA Approves ANDA210929 for Tacrolimus Oral Capsules
FDA has approved application ANDA210929 for tacrolimus oral capsules submitted by Hangzhou Zhongmei Huadong Pharmaceutical, with three discontinued dosage strengths listed.
規制動向
2026年9月18日•1分で読めます
FDA Approves ANDA210596 for VYDUO Oral Tablet (Nebivolol/Valsartan)
The FDA has approved ANDA210596 for VYDUO, an oral tablet combining nebivolol hydrochloride (5 mg) and valsartan (80 mg), submitted by Prinston Inc.
規制動向
2026年9月18日•1分で読めます
FDA Approves NexAir’s Prescription Carbon Dioxide Inhalation Product (NDA215007)
The FDA’s NDA215007 for NexAir’s carbon dioxide inhalation gas (USP) is listed with approval status AP, detailing route, dosage form, and NDC codes.
規制動向
2026年9月17日•1分で読めます
Korea issues guidance on COVID‑19 treatment supply for nursing facilities and pharmacies
Korea Disease Control Agency advises nursing homes to secure Paxlovid stocks and use Bebtelovimab based on patient condition amid rising COVID‑19 cases.
規制動向
2026年9月17日•1分で読めます
Online Mall Sells Three OTC Drugs Despite Recent Pharmacy Act Fine, Raising Safety Concerns
Three OTC medicines were found listed for sale on an online shop, even after a recent fine for illegal online dispensing, highlighting gaps in drug safety oversight.
規制動向
2026年9月17日•1分で読めます
Debate Shifts to Ownership of Warehouse‑Type Pharmacies in Korea
Korean authorities say legality of warehouse‑type pharmacies should be judged by funding sources and external influence, not just size, as corporate operators increasingly enter the market.
規制動向
2026年9月17日•1分で読めます
Yangcheon Pharmacy Association warns on govt plan to expand convenience‑store drug sales and tele‑medicine delivery
Chairwoman Yeo Yoon‑jung warned that expanding pharmacy services to convenience stores and non‑face‑to‑face medication delivery could raise concerns for members, as the rollout may extend beyond current vulnerable groups.
規制動向
2026年9月17日•1分で読めます
FDA Approves Zydus Verapamil Hydrochloride Injection (ANDA214215)
FDA has approved ANDA214215 for Zydus' injectable verapamil hydrochloride (2.5 mg/mL), a prescription IV product for cardiovascular use.
規制動向
2026年9月17日•1分で読めます
FDA Grants ANDA Approval for ICATIBANT (ANDA213773)
FDA approved ANDA213773 for the subcutaneous injectable prescription drug ICATIBANT, manufactured by Alembic Pharmaceuticals.
規制動向
2026年9月17日•1分で読めます
STERIS issues alert on RAPICIDE™ Part A bottles swelling in certain lots
STERIS reports that some RAPICIDE™ Part A bottles may bulge due to blocked vent caps, posing a risk of off‑gassing and exposure if PPE is not used.
規制動向
2026年9月17日•1分で読めます
STERIS Alerts Users to Swelling RAPICIDE™ Part A Bottles in Certain Lots
A small number of RAPICIDE™ Part A bottles may bulge due to blocked vent caps, potentially releasing vapor and exposing users; STERIS will notify affected consignees and provide replacements.